NCT05112627Completed
Immunophenotyping in Metastatic Kidney Cancer Patients Receiving Ablative Therapy
Immunophenotyping in Metastatic Renal Cell Carcinoma Patients Receiving Ablative Therapy
Source: ClinicalTrials.gov · Last updated 9 Aug 2024
Brief summary (registry, in English)
This early phase I trial evaluates blood samples to see if patients undergoing standard of care treatment with either stereotactic body radiation therapy or percutaneous ablation (using radio waves to create heat to destroy the tumor), have an increase in serum immune markers in kidney cancer. Information gained from this study may help doctors make treatment decisions for patients with kidney cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 22 Oct 2021
- Start date
- 24 Jan 2022
- Primary completion date
- 15 May 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Kidney cancer
- NCT number
- NCT05112627
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From 24 Jan 2022 to the primary completion date, 15 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior local treatment of the index metastatic lesion
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry
- Patients receiving prophylactic steroids, defined as initiation of steroids within 1 week prior to local ablative therapy start, including the first day of local ablative therapy.
- NOTE: Patients initiating steroids after the first day of local ablative therapy and within 14 days after local ablative therapy completion, will be allowed into the study and the use of steroids will be recorded.
Other
- Pregnant or nursing women
Who the study is looking for
- Histological diagnosis of primary RCC
- Histological or radiographic diagnosis of metastatic RCC
- Age \>= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-3
- Feasible vascular access as determined by study staff
- Undergoing standard of care SBRT or PCA to RCC metastatic lesion(s)
- Provide written informed consent
- Willing to consent to research blood draws
- Willing to return to enrolling institution for follow-up
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.